J. Martens

Sensitive detection of mitochondrial DNA variants for analysis of mitochondrial DNA-enriched extracts from frozen tumor tissue

M. Weerts, E. Timmermans, R. Vossen, 2018, Scientific Reports.

A kinase inhibitor screen reveals MEK1/2 as a novel therapeutic target to antagonize IGF1R-mediated antiestrogen resistance in ERα-positive luminal breast cancer.

W. V. van IJcken, J. Martens, B. van de Water, 2022, Biochemical pharmacology.

Abstract GS1-07: The genomic landscape of 501 metastatic breast cancer patients

S. Sleijfer, J. Martens, M. Smid, 2019, General Session Abstracts.

Breast cancer genomics and immuno-oncological markers to guide immune therapies.

S. Sleijfer, J. Martens, M. Smid, 2017, Seminars in cancer biology.

Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA12

A. van de Stolpe, M. Weerts, E. Timmermans, 2018, Neoplasia.

Gene expression profiles and molecular classification to predict distant metastasis and tamoxifen-resistant breast cancer

J. Martens, D. Atkins, E. Berns, 2005, Breast Cancer Research.

High protein expression of EZH2 is related to unfavorable outcome to tamoxifen in metastatic breast cancer.

S. Sleijfer, J. Martens, J. Foekens, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer

S. Sleijfer, J. Martens, J. Foekens, 2011, Breast Cancer Research and Treatment.

Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy

A Hollestelle, J. Martens, A. Sieuwerts, 2014, British Journal of Cancer.

Interconnectivity between molecular subtypes and tumor stage in colorectal cancer

J. Martens, J. Foekens, J. Tuynman, 2020, BMC cancer.